Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCLINASDAQ:CSBRNASDAQ:LJPCNASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$1.19-5.6%$1.68$1.05▼$11.25$6.79M0.7560,119 shs28,292 shsCSBRChampions Oncology$8.56-11.5%$10.15$3.60▼$11.99$144.96M0.2836,199 shs32,633 shsLJPCLa Jolla Pharmaceutical$5.73$3.07▼$6.24$155.11M2.39158,476 shs66,708 shsPRTAProthena$11.74-5.2%$14.24$11.42▼$25.42$631.93M-0.02492,239 shs955,283 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics-5.56%-17.36%-25.63%-47.58%-89.28%CSBRChampions Oncology-2.28%-9.23%-15.21%-0.12%+74.69%LJPCLa Jolla Pharmaceutical0.00%0.00%0.00%0.00%0.00%PRTAProthena-5.17%-7.19%-25.74%-15.23%-55.11%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics3.8212 of 5 stars3.53.00.04.71.70.00.6CSBRChampions Oncology3.6525 of 5 stars3.53.00.04.40.02.50.0LJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/APRTAProthena3.2844 of 5 stars4.41.00.00.02.83.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics 3.00Buy$30.002,421.01% UpsideCSBRChampions Oncology 3.00Buy$12.0040.19% UpsideLJPCLa Jolla Pharmaceutical 0.00N/AN/AN/APRTAProthena 2.75Moderate Buy$55.00368.48% UpsideCurrent Analyst Ratings BreakdownLatest BCLI, LJPC, CSBR, and PRTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/12/2025CSBRChampions OncologyCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $12.002/26/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$94.00 ➝ $110.002/21/2025PRTAProthenaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$24.00 ➝ $20.002/21/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight2/21/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$48.00 ➝ $48.002/21/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.002/7/2025PRTAProthenaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $62.00(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.20) per shareN/ACSBRChampions Oncology$50.15M2.36N/AN/A($0.14) per share-61.14LJPCLa Jolla Pharmaceutical$75.72M0.00N/A7.95($2.94) per share0.00PRTAProthena$135.16M4.68N/AN/A$10.46 per share1.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$17.19M-$4.80N/AN/AN/AN/AN/A-528.56%4/7/2025 (Estimated)CSBRChampions Oncology-$7.28M-$0.06N/A∞N/A-1.12%N/A-2.32%N/ALJPCLa Jolla Pharmaceutical$19.66M$0.1251.840.00N/A8.54%-5.46%4.00%N/APRTAProthena-$147.03M-$2.30N/AN/AN/A-90.50%-22.67%-19.68%5/6/2025 (Estimated)Latest BCLI, LJPC, CSBR, and PRTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/7/2025Q4 2024BCLIBrainstorm Cell Therapeutics-$0.49-$0.51-$0.02-$0.51N/AN/A3/11/2025Q3 2025CSBRChampions OncologyN/A$0.31N/A$0.31N/A$17.04 million2/20/2025Q4 2024PRTAProthena-$1.02-$1.08-$0.06-$1.08$7.53 million$2.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.050.05CSBRChampions OncologyN/A0.750.75LJPCLa Jolla PharmaceuticalN/A4.023.52PRTAProthenaN/A11.5211.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%CSBRChampions Oncology41.30%LJPCLa Jolla Pharmaceutical97.06%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics6.70%CSBRChampions Oncology46.98%LJPCLa Jolla Pharmaceutical36.30%PRTAProthena28.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics405.70 million5.32 millionOptionableCSBRChampions Oncology14313.82 million7.33 millionOptionableLJPCLa Jolla Pharmaceutical6124.94 million15.89 millionOptionablePRTAProthena13053.83 million38.64 millionOptionableBCLI, LJPC, CSBR, and PRTA HeadlinesRecent News About These CompaniesProthena (NASDAQ:PRTA) Stock Price Down 7.2% - Time to Sell?April 1 at 2:00 PM | marketbeat.comBrokers Issue Forecasts for Prothena FY2025 EarningsMarch 28, 2025 | marketbeat.comAnalysts Offer Predictions for Prothena FY2025 EarningsMarch 28, 2025 | americanbankingnews.comProthena (NASDAQ:PRTA) Trading 4.8% Higher - Should You Buy?March 27, 2025 | marketbeat.comBank of New York Mellon Corp Has $2.08 Million Stake in Prothena Co. plc (NASDAQ:PRTA)March 22, 2025 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Shares Sold by Connor Clark & Lunn Investment Management Ltd.March 20, 2025 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of "Moderate Buy" by AnalystsMarch 17, 2025 | marketbeat.comZacks Research Has Positive Outlook of Prothena Q1 EarningsMarch 17, 2025 | marketbeat.comZacks Research Estimates Prothena FY2027 EarningsMarch 15, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Trading Down 8.1% - Should You Sell?March 12, 2025 | marketbeat.comFoundation Wealth Management LLC Makes New $270,000 Investment in Prothena Co. plc (NASDAQ:PRTA)March 8, 2025 | marketbeat.comProthena Corporation: Multiple Failures Make It RiskyMarch 3, 2025 | seekingalpha.comProthena price target raised to $110 from $94 at Piper SandlerFebruary 26, 2025 | markets.businessinsider.comProthena Reports 2024 Financial Results and 2025 OutlookFebruary 22, 2025 | tipranks.comProthena’s Balanced Earnings Call Highlights Growth and ChallengesFebruary 22, 2025 | tipranks.comAnalysts Are Bullish on These Healthcare Stocks: Prothena (PRTA), Integer Holdings (ITGR)February 22, 2025 | markets.businessinsider.comProthena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business HighlightsFebruary 21, 2025 | uk.finance.yahoo.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), Prothena (PRTA) and Travere Therapeutics (TVTX)February 21, 2025 | markets.businessinsider.comProthena price target lowered to $20 from $24 at RBC CapitalFebruary 21, 2025 | markets.businessinsider.comProthena Corporation plc (NASDAQ:PRTA) Q4 2024 Earnings Call TranscriptFebruary 21, 2025 | msn.comProthena Q4 Earnings Miss Estimates, Pipeline Progress in FocusFebruary 21, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCLI, LJPC, CSBR, and PRTA Company DescriptionsBrainstorm Cell Therapeutics NASDAQ:BCLI$1.19 -0.07 (-5.56%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$1.24 +0.05 (+4.12%) As of 04/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Champions Oncology NASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.La Jolla Pharmaceutical NASDAQ:LJPCLa Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.Prothena NASDAQ:PRTA$11.74 -0.64 (-5.17%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$12.05 +0.31 (+2.63%) As of 04/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
